Harmony Biosciences Holdings (HRMY) EBT Margin (2020 - 2026)

Harmony Biosciences Holdings has disclosed EBT Margin across 7 years of filings, most recently posting 18.43% for Q1 2026.

• EBT Margin for Q1 2026 came in at 18.43%, down 1253.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 21.97% (down 450.0% YoY), and the FY2025 annual result was 24.76%, down 207.0% from the prior year.
• EBT Margin came in at 18.43% for Q1 2026 at Harmony Biosciences Holdings, up from 16.72% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 34.37% in Q4 2022 to a low of 6.8% in Q3 2022.
• The 5-year median for EBT Margin is 27.9% (2024), against an average of 26.05%.
• Across the five-year window, EBT Margin soared 2554 bps in 2023 and sank 2030 bps in 2024, its largest moves.
• Harmony Biosciences Holdings' EBT Margin stood at 34.37% in 2022, then slumped by 31 bps to 23.57% in 2023, then climbed by 18 bps to 27.9% in 2024, then plunged by 40 bps to 16.72% in 2025, then rose by 10 bps to 18.43% in 2026.
• The last three EBT Margin figures came in at 18.43% (Q1 2026), 16.72% (Q4 2025), and 28.18% (Q3 2025), per Business Quant data.